These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9329587)

  • 1. Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
    Micke O; Schäfer U; Wörmann B; Hiddemann W; Willich N
    Anticancer Res; 1997; 17(4B):3007-10. PubMed ID: 9329587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
    Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
    Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
    Xu J; Wang B
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
    Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
    Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
    Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
    Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
    Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia.
    Fujiwara H; Arima N; Ohtsubo H; Matsumoto T; Kukita T; Kawada H; Imaizumi R; Ozaki A; Matsushita K; Tei C
    Am J Hematol; 2002 Oct; 71(2):80-4. PubMed ID: 12353304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of soluble IL-2 receptor in the serum and bone marrow of patients with minimal residual hematological malignancies: induction under therapy with IL-2.
    Kandefer-Szerszeń M; Legieć W; Dmoszyńska A; Rzeski W
    Arch Immunol Ther Exp (Warsz); 1997; 45(5-6):443-8. PubMed ID: 9437500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
    Lehtinen T
    Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.
    Stasi R; Conforti M; Del Poeta G; Simone MD; Coppetelli U; Tribalto M; Cantonetti M; Perrotti A; Venditti A; Papa G
    Haematologica; 1992; 77(6):518-21. PubMed ID: 1289190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma.
    Pérez-Encinas M; Quintas A; Bendaña A; Rabuñal MJ; Bello JL
    Leuk Lymphoma; 1999 May; 33(5-6):551-8. PubMed ID: 10342582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum tumor necrosis factor-alpha levels in non-Hodgkin's lymphoma patients and its relationship to prognosis].
    Li D; Li G; Wang B
    Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):293-6. PubMed ID: 11038763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies.
    Nakase K; Tsuji K; Tamaki S; Tanigawa M; Ikeda T; Miyanishi E; Shiku H
    Cancer Detect Prev; 2005; 29(3):256-9. PubMed ID: 15899555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.